UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Vaso-occlusive pain management in sickle cell disease

Authors
Michael R DeBaun, MD, MPH
Elliott P Vichinsky, MD
Section Editors
Donald H Mahoney, Jr, MD
Stanley L Schrier, MD
Deputy Editor
Jennifer S Tirnauer, MD

INTRODUCTION

Acute, painful episodes are the most common reason for individuals with sickle cell disease (SCD) to seek medical attention. The frequency of pain episodes is likely to be underestimated because these episodes are managed at home, especially as individuals with SCD grow older and learn how to manage pain on their own.

No evidence-based guidelines exist for the treatment of SCD-associated acute pain episodes, either in the hospital or at home. However, reasonable strategies can be employed that are based on established principles of pain management and pharmacokinetics of opioids. Our approach to the management of painful episodes in children and adults with SCD is discussed here.

Separate topic reviews discuss the evaluation for other SCD complications that present with pain, the mechanisms of vaso-occlusive pain, and other aspects of the management of sickle cell disease:

Acute evaluation for SCD complications that present with pain – (see "Evaluation of acute pain in sickle cell disease")

Pain mechanisms – (see "Mechanisms of vaso-occlusion in sickle cell disease")

                                               
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Oct 11, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.
  2. Glassberg J, Tanabe P, Richardson L, Debaun M. Among emergency physicians, use of the term "Sickler" is associated with negative attitudes toward people with sickle cell disease. Am J Hematol 2013; 88:532.
  3. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008; 148:94.
  4. Smith WR, McClish DK, Dahman BA, et al. Daily home opioid use in adults with sickle cell disease: The PiSCES project. J Opioid Manag 2015; 11:243.
  5. Yusuf HR, Atrash HK, Grosse SD, et al. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007. Am J Prev Med 2010; 38:S536.
  6. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am 2005; 19:785.
  7. Redwood AM, Williams EM, Desal P, Serjeant GR. Climate and painful crisis of sickle-cell disease in Jamaica. Br Med J 1976; 1:66.
  8. Resar LM, Oski FA. Cold water exposure and vaso-occlusive crises in sickle cell anemia. J Pediatr 1991; 118:407.
  9. Ibrahim AS. Relationship between meteorological changes and occurrence of painful sickle cell crises in Kuwait. Trans R Soc Trop Med Hyg 1980; 74:159.
  10. Amjad H, Bannerman RM, Judisch JM. Letter: Sickling pain and season. Br Med J 1974; 2:54.
  11. Westerman MP, Bailey K, Freels S, et al. Assessment of painful episode frequency in sickle-cell disease. Am J Hematol 1997; 54:183.
  12. Yoong WC, Tuck SM. Menstrual pattern in women with sickle cell anaemia and its association with sickling crises. J Obstet Gynaecol 2002; 22:399.
  13. Smith WR, Bauserman RL, Ballas SK, et al. Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea. Pain 2009; 146:91.
  14. Cohen RT, DeBaun MR, Blinder MA, et al. Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease. Blood 2010; 115:3852.
  15. Glassberg J, Spivey JF, Strunk R, et al. Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms. J Pediatr Hematol Oncol 2006; 28:481.
  16. Nolan VG, Zhang Y, Lash T, et al. Association between wind speed and the occurrence of sickle cell acute painful episodes: results of a case-crossover study. Br J Haematol 2008; 143:433.
  17. Jones S, Duncan ER, Thomas N, et al. Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. Br J Haematol 2005; 131:530.
  18. Yallop D, Duncan ER, Norris E, et al. The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. Br J Haematol 2007; 136:844.
  19. Zempsky WT. Evaluation and Treatment of Sickle Cell Pain in the Emergency Department: Paths to a Better Future. Clin Pediatr Emerg Med 2010; 11:265.
  20. http://americanpainsociety.org/education/guidelines/sickle-cell-guideline.
  21. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.
  22. McClish DK, Smith WR, Dahman BA, et al. Pain site frequency and location in sickle cell disease: the PiSCES project. Pain 2009; 145:246.
  23. Wilkie DJ, Molokie R, Boyd-Seal D, et al. Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease. J Natl Med Assoc 2010; 102:18.
  24. Ballas SK, Delengowski A. Pain measurement in hospitalized adults with sickle cell painful episodes. Ann Clin Lab Sci 1993; 23:358.
  25. Luffy R, Grove SK. Examining the validity, reliability, and preference of three pediatric pain measurement tools in African-American children. Pediatr Nurs 2003; 29:54.
  26. Ho K, Spence J, Murphy MF. Review of pain-measurement tools. Ann Emerg Med 1996; 27:427.
  27. Brandow AM, Farley RA, Panepinto JA. Neuropathic pain in patients with sickle cell disease. Pediatr Blood Cancer 2014; 61:512.
  28. Ballas SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin 1995; 19:323.
  29. Dampier C, Palermo TM, Darbari DS, et al. AAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain. J Pain 2017; 18:490.
  30. Labbé E, Herbert D, Haynes J. Physicians' attitude and practices in sickle cell disease pain management. J Palliat Care 2005; 21:246.
  31. Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage 1997; 14:168.
  32. Pack-Mabien A, Labbe E, Herbert D, Haynes J Jr. Nurses' attitudes and practices in sickle cell pain management. Appl Nurs Res 2001; 14:187.
  33. Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology Am Soc Hematol Educ Program 2005; :58.
  34. Sins JWR, Mager DJ, Davis SCAT, et al. Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: A systematic review. Blood Advances 2017; 1:1598.
  35. Crosby LE, Simmons K, Kaiser P, et al. Using Quality Improvement Methods to Implement an Electronic Medical Record (EMR) Supported Individualized Home Pain Management Plan for Children with Sickle Cell Disease. J Clin Outcomes Manag 2014; 21:210.
  36. http://www.nhlbi.nih.gov/health-pro/guidelines/current/management-sickle-cell-disease.htm (Accessed on September 30, 2014).
  37. Brousseau DC, McCarver DG, Drendel AL, et al. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr 2007; 150:623.
  38. Goodman E. Use of ketorolac in sickle-cell disease and vaso-occlusive crisis. Lancet 1991; 338:641.
  39. Wright SW, Norris RL, Mitchell TR. Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. Ann Emerg Med 1992; 21:925.
  40. Perlin E, Finke H, Castro O, et al. Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis. Am J Hematol 1994; 46:43.
  41. Hardwick WE Jr, Givens TG, Monroe KW, et al. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care 1999; 15:179.
  42. Beiter JL Jr, Simon HK, Chambliss CR, et al. Intravenous ketorolac in the emergency department management of sickle cell pain and predictors of its effectiveness. Arch Pediatr Adolesc Med 2001; 155:496.
  43. Bartolucci P, El Murr T, Roudot-Thoraval F, et al. A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood 2009; 114:3742.
  44. Schaller S, Kaplan BS. Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. Pediatr Emerg Care 1998; 14:416.
  45. Simckes AM, Chen SS, Osorio AV, et al. Ketorolac-induced irreversible renal failure in sickle cell disease: a case report. Pediatr Nephrol 1999; 13:63.
  46. Tanabe P, Hafner JW, Martinovich Z, Artz N. Adult emergency department patients with sickle cell pain crisis: results from a quality improvement learning collaborative model to improve analgesic management. Acad Emerg Med 2012; 19:430.
  47. Raphael JL, Oyeku SO. Sickle cell disease pain management and the medical home. Hematology Am Soc Hematol Educ Program 2013; 2013:433.
  48. National Heart, Lung, and Blood Institute. The Management of Sickle Cell Disease, 4th ed, National Institutes of Health, Bethesda, MD 2002.
  49. Bijur PE, Kenny MK, Gallagher EJ. Intravenous morphine at 0.1 mg/kg is not effective for controlling severe acute pain in the majority of patients. Ann Emerg Med 2005; 46:362.
  50. Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. Ann Intern Med 1992; 116:364.
  51. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood 2000; 95:1130.
  52. Wright J, Bareford D, Wright C, et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol 2004; 126:878.
  53. Co JP, Johnson KB, Duggan AK, et al. Does a clinical pathway improve the quality of care for sickle cell anemia? Jt Comm J Qual Saf 2003; 29:181.
  54. Jayaram A, Nagel RW, Jasty R. Impact of clinical pathway on quality of care in sickle cell patients. J Pediatr Hematol Oncol 2010; 32:537.
  55. Morrissey LK, Shea JO, Kalish LA, et al. Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer 2009; 52:369.
  56. Frei-Jones MJ, Field JJ, DeBaun MR. Multi-modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate. Pediatr Blood Cancer 2009; 53:401.
  57. Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs patient-controlled analgesia for sickle cell crisis pain. Comparison in patients in the emergency department. Arch Intern Med 1991; 151:1373.
  58. van Beers EJ, van Tuijn CF, Nieuwkerk PT, et al. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol 2007; 82:955.
  59. Melzer-Lange MD, Walsh-Kelly CM, Lea G, et al. Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. Pediatr Emerg Care 2004; 20:2.
  60. HATCH FE, DIGGS LW. FLUID BALANCE IN SICKLE-CELL DISEASE. Arch Intern Med 1965; 116:10.
  61. Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997; 89:1787.
  62. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254.
  63. Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review. Am J Forensic Med Pathol 2007; 28:168.
  64. Ataga KI, Orringer EP. Renal abnormalities in sickle cell disease. Am J Hematol 2000; 63:205.
  65. Maurel S, Stankovic Stojanovic K, Avellino V, et al. Prevalence and correlates of metabolic acidosis among patients with homozygous sickle cell disease. Clin J Am Soc Nephrol 2014; 9:648.
  66. Batlle D, Itsarayoungyuen K, Arruda JA, Kurtzman NA. Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies. Am J Med 1982; 72:188.
  67. Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. Cochrane Database Syst Rev 2012; :CD005406.
  68. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162:276.
  69. Brown SE, Weisberg DF, Balf-Soran G, Sledge WH. Sickle cell disease patients with and without extremely high hospital use: pain, opioids, and coping. J Pain Symptom Manage 2015; 49:539.
  70. Okorji LM, Muntz DS, Liem RI. Opioid prescription practices at discharge and 30-day returns in children with sickle cell disease and pain. Pediatr Blood Cancer 2017; 64.
  71. Brodsky MA, Rodeghier M, Sanger M, et al. Risk Factors for 30-Day Readmission in Adults with Sickle Cell Disease. Am J Med 2017; 130:601.e9.
  72. Frei-Jones MJ, Field JJ, DeBaun MR. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatr Blood Cancer 2009; 52:481.
  73. Leschke J, Panepinto JA, Nimmer M, et al. Outpatient follow-up and rehospitalizations for sickle cell disease patients. Pediatr Blood Cancer 2012; 58:406.
  74. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 2005; 79:17.
  75. Chen E, Cole SW, Kato PM. A review of empirically supported psychosocial interventions for pain and adherence outcomes in sickle cell disease. J Pediatr Psychol 2004; 29:197.
  76. Brandow AM, Weisman SJ, Panepinto JA. The impact of a multidisciplinary pain management model on sickle cell disease pain hospitalizations. Pediatr Blood Cancer 2011; 56:789.
  77. Moody K, Abrahams B, Baker R, et al. A Randomized Trial of Yoga for Children Hospitalized With Sickle Cell Vaso-Occlusive Crisis. J Pain Symptom Manage 2017; 53:1026.
  78. Mann-Jiles V, Thompson K, Lester J. Sleep impairment and insomnia in sickle cell disease: a retrospective chart review of clinical and psychological indicators. J Am Assoc Nurse Pract 2015; 27:441.
  79. Dampier C, Ely B, Brodecki D, O'Neal P. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain 2002; 3:461.
  80. Ballas SK, Bauserman RL, McCarthy WF, et al. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage 2010; 40:870.
  81. Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manag 2005; 10:133.
  82. Jones RC 3rd, Lawson E, Backonja M. Managing Neuropathic Pain. Med Clin North Am 2016; 100:151.
  83. Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag 2003; 8:149.
  84. Moulin D. Use of methadone for neuropathic pain. Pain Res Manag 2003; 8:131.
  85. Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev 2012; :CD001916.
  86. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm566084.htm (Accessed on July 07, 2017).
  87. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208587s000lbl.pdf (Accessed on July 07, 2017).
  88. https://clinicaltrials.gov/ct2/show/NCT01179217?term=glutamine&cond=sickle&rank=2 (Accessed on July 10, 2017).
  89. Niihara Y, Zerez CR, Akiyama DS, Tanaka KR. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol 1998; 58:117.
  90. Niihara Y, Macan H, Eckman JR, et al. L-Glutamine therapy reduces hospitalization for sickle cell anemia and sickle β°-thalassemia patients at six months - A phase II randomized trial. Clin Pharmacol Biopharm 2014; 3:116.
  91. Niihara Y, Matsui NM, Shen YM, et al. L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disord 2005; 5:4.
  92. Allen Liles E, Kirsch J, Gilchrist M, Adem M. Hospitalist management of vaso-occlusive pain crisis in patients with sickle cell disease using a pathway of care. Hosp Pract (1995) 2014; 42:70.
  93. Krishnamurti L, Smith-Packard B, Gupta A, et al. Impact of individualized pain plan on the emergency management of children with sickle cell disease. Pediatr Blood Cancer 2014; 61:1747.
  94. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med 2017; 376:429.
  95. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019645s019lbl.pdf.
  96. Baddam S, Aban I, Hilliard L, et al. Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis. Pediatr Nephrol 2017.
  97. Allon M, Lawson L, Eckman JR, et al. Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia. Kidney Int 1988; 34:500.
  98. Brousseau DC, Scott JP, Badaki-Makun O, et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood 2015; 126:1651.
  99. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330:733.
  100. Glassberg J, Minnitti C, Cromwell C, et al. Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: A triple-blind, randomized trial. Am J Hematol 2017; 92:622.
  101. Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2003; 289:1136.
  102. Head CA, Swerdlow P, McDade WA, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol 2010; 85:800.
  103. Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011; 305:893.
  104. Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 2013; 98:1375.
  105. Claster S, Godwin MJ, Embury SH. Risk of altitude exposure in sickle cell disease. West J Med 1981; 135:364.
  106. Tewari S, Brousse V, Piel FB, et al. Environmental determinants of severity in sickle cell disease. Haematologica 2015; 100:1108.
  107. Ware M, Tyghter D, Staniforth S, Serjeant G. Airline travel in sickle-cell disease. Lancet 1998; 352:652.
  108. Aerospace Medical Association Medical Guidelines Task Force. Medical Guidelines for Airline Travel, 2nd ed. Aviat Space Environ Med 2003; 74:A1.
  109. Heeney MM, Hoppe CC, Abboud MR, et al. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med 2016; 374:625.
  110. Murphy JD, Gelfand HJ, Bicket MC, et al. Analgesic efficacy of intravenous naloxone for the treatment of postoperative pruritus: a meta-analysis. J Opioid Manag 2011; 7:321.
  111. Cepeda MS, Alvarez H, Morales O, Carr DB. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain 2004; 107:41.
  112. Sartain JB, Barry JJ, Richardson CA, Branagan HC. Effect of combining naloxone and morphine for intravenous patient-controlled analgesia. Anesthesiology 2003; 99:148.
  113. Gan TJ, Ginsberg B, Glass PS, et al. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997; 87:1075.
  114. Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg 2005; 100:953.
  115. Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333:699.
  116. Kjellberg F, Tramèr MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001; 18:346.
  117. Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood 2008; 111:997.
  118. Payne R. Pain management in sickle cell disease. Rationale and techniques. Ann N Y Acad Sci 1989; 565:189.
  119. Okpala I, Tawil A. Management of pain in sickle-cell disease. J R Soc Med 2002; 95:456.
  120. Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41:949.
  121. Vichinsky EP, Johnson R, Lubin BH. Multidisciplinary approach to pain management in sickle cell disease. Am J Pediatr Hematol Oncol 1982; 4:328.
  122. Kavanagh PL, Sprinz PG, Wolfgang TL, et al. Improving the Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department. Pediatrics 2015; 136:e1016.
  123. Murphy A, O'Sullivan R, Wakai A, et al. Intranasal fentanyl for the management of acute pain in children. Cochrane Database Syst Rev 2014; :CD009942.
  124. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28:497.
  125. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 1986; 292:1548.
  126. Sear JW, Hand CW, Moore RA, McQuay HJ. Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. Br J Anaesth 1989; 62:28.
  127. Grass JA. Patient-controlled analgesia. Anesth Analg 2005; 101:S44.
  128. Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001; 15:26.
  129. Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995; 10:184.
  130. Fainsinger R, Schoeller T, Boiskin M, Bruera E. Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993; 9:53.
  131. Mercadante S, Caligara M, Sapio M, et al. Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage 1997; 13:241.
  132. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 2005; 33:311.